Background. Postamputation pain is highly prevalent after limb amputation with neuropathic nature; calcitonin may effectively relieve many neuropathic pain states.
Introduction
A dramatic increase in the number of patients with type II diabetes is being observed worldwide. A consequent increase in the burden of diabetes-related complications is inevitable [1] . Diabetes increases the risk of vascular complication by four times, including peripheral vascular disease characterized by narrowing or occlusion of the arteries resulting in gradual reduction of blood supply to the limbs [2] . Diabetic patients have a nearly fifteen times higher risk of lower extremity amputation than the general population [3] . Postamputation pain remains an extremely challenging pain condition to treat. More than 80% of limb amputations develop phantom pain, which is pain referred to the missing limb [4] . The mechanisms of phantom limb pain are not fully understood; however, supraspinal, spinal, and peripheral mechanisms are involved. Treatment of phantom pain is generally not successful, so the prevention of phantom pain is our future hope to decrease its incidence [5] .
Calcitonin is a 32 amino acid peptide hormone secreted by the para-follicular cells of the thyroid gland; it is an endogenous regulator of calcium homeostasis. Since its discovery in 1961, it has been used for treatment of different diseases. Twenty years later, its analgesic action was demonstrated after intravenous, epidural, or subarachnoid injection. Calcitonin may effectively relieve chronic pain states as it affects the release of endorphin and other factors with catecholaminergic and serotoninergic terminals [6] .
Our study hypothesis is to evaluate the preventive value of epidural calcitonin on postoperative pain, the grade of chronic phantom pain, and the development of hyperalgesia and allodynia in patients undergoing lower limb amputation under combined spinal anesthesia.
Methods
The study was approved by an investigational review board of the Faculty of Medicine, Tanta University; an informed written consent was obtained from all patients participating in the study. This study was registered in the Clinical Trail Registry (clinicaltrail.gov) with unique identification number NCT02115360. A prospective randomized double-blind clinical trial was carried out in a cohort of 60 diabetic patients of both genders suffering from vascular insufficiency of one or both lower limbs who underwent minor or major lower limb amputation. Minor amputations were defined as those amputations occurring below the ankle level and were categorized into amputation of the hallux, toes, metatarsals, and midfoot.
Patients were divided randomly into two equal groups: an epidural bupivacaine-calcitonin-fentanyl (BCF) group and a bupivacaine-fentanyl (BF) group, 30 patients in each group. Randomization was performed by random numbers using sealed envelopes without sex stratification. Sealed envelope indicated group assignment. Between March 2014 and August 2014, an independent anesthesiologist, who did not participate in the study design or data collection, read the number contained in each envelope and made group assignments, blindly randomizing patients into the two groups until reaching the required number of patients (30) in each group. Patients were followed up until August 2015. Patients with contraindications to performing an epidural block such as coagulation abnormalities or spinal deformities and patients allergic to local anesthetics were excluded from the study.
Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using a 16 gauge Tuohy needle. An injection of 1 mL hyperbaric bupivacaine was made into the subarachnoid space through a 25 gauge spinal needle, then 10 mL 0.5% bupivacaine, 100 micrograms of fentanyl, and 100 iu of calcitonin (Cactonin, Stadapharm, Stada, Germany) were injected epidurally in the bupivacain-calcitonin-fentanyl (BCF) group, while 10 mL 0.5% bupivacaine, 100 micrograms of fentanyl, and 1 mL normal saline were injected epidurally in the bupivacain-fentanyl (BF) group. Then a 16 G Portex catheter was inserted for purposes of postoperative epidural analgesia daily on day 1 and day 2. Ten mL 0.5% bupivacaine and 100 iu of calcitonin were injected epidurally in the BCF group, while 10 mL 0.5% bupivacaine and 1 mL normal saline were injected epidurally in the BF group, through the epidural catheter daily for the first two postoperative days.
The injection was given with unlabeled syringes prepared by an independent anaesthologist not involved in the patients' care or in pain assessment. The specific treatment given was unknown to the patient, anesthesiologist, surgeon, or nurses in charge of pain assessment. All patients and personnel involved in patient management and data collection were unaware of the group to which the patient was assigned.
On the evening before surgery, patients were instructed about the use of a 10 cm visual analog scale (VAS; 0 ¼ no pain to 10 ¼ worst possible pain). Patients were premedicated with midazolam (0.01 mg/kg) two hours before surgery. A preloading with 500 mL lactated ringer solution was performed. Postoperative pain was assessed on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain) by independent physicians who were completely blinded to patients' group assignments and were not informed of the study design. All patients received 15 mg/kg i.v. acetaminophen every six hours; the first dose was be given 40 minutes before the end of surgery. Supplementary doses of acetaminophen i.v. were given to patients with a VAS scores higher than 4. Any episodes of bradycardia (HR < 50 beats/minute), hypotension (SBP < 90 mmHg), nausea, vomiting, and excessive sedation were recorded.
Severity of phantom limb pain was graded using the four-grade scale. Pin-prick hyperalgesia and allodynia at one week, one month, three months, and six months were tested after surgery during a follow-up visit by independent physicians who were completely blinded to patients' group assignments, not sharing in the study design.
Severity of phantom pain was graded as follows: grade I (mild, intermittent paraesthesias that do not interfere with normal activity, work, or sleep); grade II (paraesthesias that are uncomfortable and annoying but do not interfere with activities or sleep; grade III (pain that is of sufficient intensity, frequency, or duration to be distressful); and grade IV (nearly constant severe pain that interferes with normal activity and sleep) [7] .
Pin-prick hyperalgesia was tested using a von Frey hair on the skin starting from outside the hyperalgesic area where no pain sensation is experienced and advancing toward the center of the incision until the patient reported a distinct change in perception and feeling pain. Pin-prick hyperalgesia was compared in two regions of the body: a control site on the contralateral inner thigh and a test site approximately 10 cm from the surgical wound. Allodynia was tested by a brush, which was applied in the same manner as the von Frey hair.
The primary outcome was the degree of postoperative pain score using VAS in the two groups. The secondary outcomes measures were the degree of phantom limb pain, pin-prick hyperalgesia, and allodynia after surgery. All adverse events related to surgery and the regional anesthetic techniques were recorded.
Statistical Analysis
The collected data were organized, tabulated, and statistically analyzed using SPSS version 19 (Statistical Package for Social Studies; IBM, Chicago, IL, USA). For numerical values, the range, mean, and standard deviations were calculated. The differences between two mean values were used using the Student's t test. Differences of mean values at different periods of followup were tested using repeated measurement analysis of variance (F), and when found significant Bonferroni test was used to compare between each two groups. For categorical variable, the number and percentage were calculated and differences between subcategories were tested using Fisher's or Monte Carlo exact tests. Testing difference in categorical variables at different periods of follow-up was done using Friedman's chisquare test. The level of significance was adopted at a P value of less than 0.05.
Sample Size Analysis
A sample size analysis determined that 27 patients per group are required to detect a difference in VAS of at least 35% between groups with a power of 80%, a of 0.05, and allocation ratio of 1:1, so we included 30 patients per group.
Results
The study population consisted of 60 patients scheduled for lower limb amputation. There were no significant changes between groups regarding patients' demographics (age, sex, weight, and height) including type and duration of surgery (Table 1) .
There was no significant change regarding the VAS scale between groups throughout the pre-and postoperative periods. In the BCF group, there was a significant reduction in the mean VAS scale in the immediate, 12-hour, and 24-hour postoperative VAS in comparison with the preoperative values. (P ¼ 0.001). In the BF group, there was a significant reduction in VAS scale in the immediate and 12-hour postoperative VAS in comparison with the preoperative value (P ¼ 0.001) ( Table 2 ).
There was a statistically significant change regarding grades of phantom pain within the studied groups throughout the follow-up period (P ¼ 0.044 and 0.001, respectively). One month after surgery, 29 patients in the BCF group were grade I in comparison with 27 patients in the BF group (P ¼ 0.612). Three months after surgery, 28 patients in the BCF group were grade I in comparison with 24 patients in the BF group (P ¼ 0.254). Six months after surgery, 27 patients were grade I in the BCF group in comparison with 19 patients in the BF group (P ¼ 0.033) One year after surgery, 26 patients were grade I in the BCF group in comparison with 15 patients in the BF group (P ¼ 0.001) ( Table 3) .
There was an increase in the number of patients who developed allodynia within the studied groups throughout the postoperative period (P ¼ 0.036 and 0.001, respectively). One month after surgery, three patients in the BF group developed allodynia in comparison with 1 patient in the BCF group. (P ¼ 0.612) Three months after surgery, six patients developed allodynia in the BF group in comparison with two patients in the BCF group (P ¼ 0.254). Six months after surgery, 12 patients developed allodynia in the BF group in comparison with four patients in the BCF group (P ¼ 0.039). One year after surgery, 15 patients developed allodynia in the BF group in comparison with five patients in the BCF group (P ¼ 0.013) ( Table 4) .
There was an increase in the number of patients who developed hyperalgesia throughout the postoperative period in both groups (P ¼ 0.062 and 0.001, respectively). One month after surgery, two patients in the BF group developed hyperalgesia in comparison with one patient in the BCF group (P ¼ 1.00). Three months after surgery, five patients developed hyperalgesia in the BF group in comparison with three patients in the BCF group (P ¼ 0.706). Six months after surgery, 11 patients developed hyperalgesia in the BF group in comparison with five patients in the BCF group (P ¼ 0.143). One year after surgery, 14 patients developed hyperalgesia in the BF group in comparison with five patients in the BCF group (P ¼ 0.025) ( Table 5) .
Discussion
This study is the first to evaluate the effectiveness of epidural calcitonin in the prevention of phantom limb pain in patients undergoing lower limb amputation under combined spinal epidural anesthesia. The study showed improvement in the grade of phantom pain as well as reduction in the incidence of allodynia and hyperalgesia in patients who received epidural calcitonin. Our study has some limitations. The first limitation is the mixed nature of patients undergoing both major and minor amputation in each group. The second limitation is the short follow-up period, which is limited to one year to avoid loss of patients during the follow-up period. The third limitation is dependence on a sample size calculation based upon changes in acute pain tested by VAS.
The etiology of phantom pain is multifactorial, with peripheral and central neuronal mechanisms being theorized as responsible. Peripherally, spontaneous and abnormal evoked activities are detected in nerve-end neuromas. The increased barrage from neuromas may induce long-term central potentiation in the dorsal horn, leading to spontaneous neuronal activity, enhanced spinal cord metabolic activity, and expansion of receptive fields, in addition to central changes in cortical and subcortical structures [7] .
Calcitonin binds to G protein-coupled receptor, which is similar in structure to an opioid receptor, with cyclic AMP and calcium acting as secondary messengers. The analgesic action of epidural calcitonin is mediated through specific binding sites in the spinal cord and supraspinal areas. The correlation between the analgesic activity and the localization of calcitonin binding sites related to sensory transmission suggest a role of calcitonin as an additional possible endogenous modulator of pain. Calcitonin activates endogenous opioid mediators such as delta or kappa opioid receptors. On the other hand, there is good evidence that the CNS serotoninergic system may be involved in calcitonininduced analgesia [8] .
Calcitonin receptors are present on serotonergic neurons in the thalamus, the periaqueductal gray matter, the nucleus giganto-cellularis, and raphe nucleus, which are the descending pain inhibitory pathways. However, modification of cholinergic, protein phosphorylation, cyclooxygenase inhibition, and b-endorphin precursor production and inhibition of prostaglandin E2 synthesis are involved in its analgesic potential. Calcitonin also interacts with opioid receptors with prominent analgesic properties [9] . The similarity of phantom pain to preamputation pain is the concept behind the preventive effect of epidural analgesia. It is hypothesized that preamputation pain may initiate an imprint in the central nervous system that may be responsible for persistent pain after amputation, so aborting the formation of this brain stigma may prevent phantom pain [10] .
Calcitonin is an effective analgesic agent when used via epidural infusion. In their study, Gabopoulou et al. [6] evaluated the role of epidural analgesia in patients undergoing elective total hip arthroplasty under epidural anesthesia. Postoperative analgesia was provided either with calcitonin alone, calcitonin and bupivacaine, or a conventional mixture of opioids and bupivacaine, and it was concluded that patients who received epidural calcitonin had very little or no postoperative pain (VAS > 3). Maytorena et al. [11] , in their study regarding the use of subarchnoid and epidural injection of calcitonin in patients with metastatic cancer pain, described significant pain relief after epidural calcitonin injection in patients refractory to traditional therapy.
Many clinical studies evaluated the role of preoperative epidural block for prevention of phantom pain. Bach et al. [12] studied the value of lumbar epidural blockade with bupivacaine and morphine for 72 hours prior to the operation for prevention of phantom pain. All the patients in the lumbar epidural blockade group were pain free at the one-year follow-up, so they concluded that preoperative lumbar epidural blockade with bupivacaine and morphine reduces the incidence of phantom limb pain in the first year after operation. Jahangiri et al. [13] in another study evaluated the role of perioperative epidural infusion of morphine and bupivacaine in preventing phantom limb pain and concluded that perioperative epidural infusion of diamorphine, clonidine, and bupivacaine was effective in reducing the incidence of phantom pain after amputation. Nikolajsen et al. [14] examined the effect of preoperative extradural bupivacaine and morphine on postoperative stump sensation and found that extradural block reduced the immediate postoperative pain scale without long-term prophylactic effect on hyperalgesia, allodynia, or wind-up-like pain; they explained these findings as due to biases in patient selection and the limited number of patients in the study. Jaeger et al. [15] studied the role of preemptive infusion of salmon calcitonin for patients who underwent major amputations, found that more than 75% of their patients were pain free during one year of follow-up, and concluded that calcitonin is a valuable treatment for phantom limb pain in the early postoperative period. Simanski et al. [16] examined the value of intravenous Yousef and Aborahma application of salmon-calcitonin in patients with severe phantom limb pain. Postinfusion evaluation revealed immediate and long-term reduction of pain intensity using a numeric rating scale at three, six, and 12 months of follow-up. Concerning the safety of use of calcitonin, multiple studies used epidural calcitonin without reporting any hazards regarding toxicity or harms [6, 8, 11, 12] .
Multiple studies have used neuraxial calcitonin for their pain-relieving effects [8, 17, 18, 11, 19] . Subarachnoid calcitonin has been used for relief of acute postoperative pain with significant decrease in analgesic requirements during the first 72 hours after surgery [8] . Another study reported that neuraxial calcitonin in patients suffering from chronic, intractable oncological pain produced effective analgesia and considered neuraxial calcitonin a practical solution in the management of intractable oncological pain [17, 18, 11, 19] .
Conclusion
In a blinded clinical trial, the preventive use of epidural calcitonin in patients undergoing lower limb amputation under combined spinal anesthesia improved the grade of phantom pain and reduced the incidence of allodynia and hyperalgesia during one year of follow-up.
